Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 938 results for "for merck"

Merck buys Swiss biotech with promising cancer drug
Miami Herald

OncoEthix acquired by Merck

OncoEthix SA, a Switzerland-based clinical stage biotechnology company engaged in the development of new drugs for cancer treatment, has been acquired by subsidiary of Merck & Co., Inc., a US-based research-driven pharmaceutical company. Pursuant to ... Individual.com, 6 hours ago
Merck buys Swiss biotech firm Seeking Alpha, 13 hours ago
[x]  

475 images for for merck

Business Standard, 12 hours ago
Jutia Group, 8 hours ago
One News Page United Kingdom, 7 hours ago
Proactive Investors USA, 5 hours ago
Bidness Etc, 2 days ago
Boston Globe, 1 day ago
Med India, 6 days ago
Bio Spectrum Asia, 5 days ago
Boston Globe, 4 days ago
StarAfrica.com, 6 days ago
Business Standard

Anand Nambiar is new MD of Merck

Drug firm Merck on Thursday appointed Anand Nambiar as its new Managing Director in place of Dr Claus-Dieter Boedecker who resigned from the company. Claus-Dieter Boedecker, Managing Director of the company, has submitted a letter to the Board ...
 Hindu Business Line13 hours ago Merck appoints Anand Nambiar as Managing Director  Business Standard14 hours ago REFILE-BRIEF-India's Merck Ltd says board recommends to appoint Anand Nambiar as MD  Reuters UK17 hours ago Correction - India caps prices of 52 more "essential" drugs - NPPA  Business Standard6 days ago
[x]  

ENUM: Enumeral Enters into Collaboration with Merck for Drug Response Prediction via Human Immune Profiling

By Anthony Schwartz, PhD OBB:ENUM Enumeral Biomedical Holdings, Inc. ( ENUM )is a biotechnology company focused on discovering and developing novel immunotherapies for the treatment of cancer and autoimmune diseases. On December 18, 2014, ...
 Yahoo! Finance6 hours ago Enumeral Biomedical And Merck & Co. Form Collaboration For Predicting Clinical Drug Response With Human-Driven Immune Profiling Platform  BioSpace7 hours ago Enumeral, Merck in Immune Profiling Pact  Contract Pharma8 hours ago Enumeral and Merck Form Collaboration for Predicting Clinical Drug..  ADVFN Australia13 hours ago
[x]  
Citybizlist

Market Update: Merck & Co Inc (NYSE:MRK) Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers

at 07:30 AM EST [Business Wire] Merck , known as MSD outside the United States and Canada, announced today that it has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology . . . → ...
 BioSpace9 hours ago Merck Acquires OncoEthix  Citybizlist11 hours ago Merck & Co. Snaps Up Swiss Biotech In $375 Buyout Deal  BioSpace12 hours ago Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers  SearchBug14 hours ago
[x]  
Proactive Investors USA

MERCK : Acquires OncoEthix for Up to $375 Million

By Angela Chen Merck & Co. acquired privately held OncoEthix for up to $375 million, its latest push into the oncology market as the pharmaceutical giant continues bolstering its research-and-development pipeline. OncoEthix is a Swiss-based ...
 4 Traders13 hours ago Merck & Co. buys cancer drug developer OncoEthix for up to $375 million  FirstWord Pharma13 hours ago The Wall Street Journal: Merck acquires OncoEthix for up to $375 million  Austin American Statesman12 hours ago Merck Acquires OncoEthix for Up to $375 Million  ADVFN India12 hours ago
[x]  

Merck acquires OncoEthix

Merck & Co., Inc., through its subsidiary, has acquired OncoEthix SA, a Switzerland-based clinical stage biotechnology company engaged in the development of new drugs for cancer treatment. Merck is a US-based research-driven pharmaceutical company ...
 Individual.com6 hours ago

Next Resistance Level for Merck (MRK) is $58.57

Merck (NYSE:MRK) has opened bullishly above the pivot of $57.33 today and has reached the first level of resistance at $58.10. Investors may be interested in a cross of the next upside pivot targets of $58.57
 Individual.com7 hours ago

Merck (MRK) Showing Support Near $56.09

The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artifical Intelligence Center found a trading opportunity with Merck & Co Inc. (http://www.marketintelligencecenter.com/symbol/MRK"MRK) that should provide a ...
 Individual.com12 hours ago Merck (MRK) Trading Near $56.01 Support Level  Individual.com2 days ago

Options Traders Buy the Pullback in Pharmaceuticals Giant Merck

By David Russell | 12/18/14 - 05:45 AM EST NEW YORK -- Option traders bought the pullback in Merck ( MRK ) on Wednesday. OptionMonster's Heat Seeker system detected the purchase of about 10,000 February 62.50 calls for 39 cents. The big block ...
 TheStreet.com15 hours ago Call buyers take a dose of Merck  Option Monster14 hours ago

Merck's 3.2% Yield Is The Only Reason To Own The Stock

Summary Merck will struggle to hit EPS growth estimates going forward. Stagnant EPS means the company's shares are overvalued and should trade down into the $50 area. I'd be a buyer at $50 for the yield but the business doesn't excite me. ...
 Seeking Alpha20 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less